Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Diesel engine exhaust (DEE) is classified as a Group I carcinogen, yet direct experimental evidence that DEE induce carcinogenesis is lacking. Here, it is innovatively discovered that 120 µg mL DEE exposure for 20 weeks, original bronchial epithelial cells exhibit abnormal morphology, form colonies in soft agar, and readily develop the lumps under the subcutaneous tissue of immunodeficient mice, which are pathologically confirmed as lung squamous cell carcinoma. Whole genome sequencing and RNA sequencing identify DEE-induced mutational signatures (DBS3, ID1/ID2), associated with polymerase epsilon (POLE) exonuclease domain mutations and mismatch repair (MMR) deficiency. Besides, 52 exonic mutations, 734 copy number variations (CNVs), and 2519 differentially expressed genes (DEGs) are discovered which are enriched in the suppressed DNA damage repair pathways and the activated lung cancer related signaling pathways including JAK-STAT, PI3K-Akt, MAPK in the DEE-induced malignant transformed cells. Further assays confirm DEE-induced malignant transformed cells harbor both POLE and MMR defects, leading to high mutation burden and genomic instability. Additionally, POLE deficiency exacerbates DEE-induced DNA damage and genomic instability, promoting the cell malignant transformation. This study highlights the importance of gene-environment interaction in carcinogenesis and emphasizes the critical role of POLE deficiency in DEE-induced malignant transformation of lung cells.

Download full-text PDF

Source
http://dx.doi.org/10.1002/advs.202415943DOI Listing

Publication Analysis

Top Keywords

pole deficiency
12
genomic instability
12
malignant transformation
12
dee-induced malignant
12
deficiency exacerbates
8
diesel engine
8
bronchial epithelial
8
epithelial cells
8
dna damage
8
malignant transformed
8

Similar Publications

Distinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study.

Gynecol Oncol

September 2025

Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Pathology, Helsinki University Hospital and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Objective: This study evaluated time to progression and post-recurrence disease-specific survival in molecularly classified endometrial carcinoma to improve understanding of disease biology and factors influencing tumor aggressiveness.

Methods: In this retrospective cohort study, immunohistochemistry and polymerase-ϵ (POLE) sequencing were used for molecular classification and determination of estrogen receptor and programmed death-ligand 1 (PD-L1) expression.

Results: We identified 1146 patients with molecularly classified endometrial carcinoma, of whom 220 (19.

View Article and Find Full Text PDF

Molecular classification and fertility-sparing outcomes in endometrial cancer and atypical endometrial hyperplasia.

Biomol Biomed

August 2025

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Medical Key Laboratory for Prevention and Treatment of Malignant Gynecological Tumor, China.

Molecular classification has emerged as a critical tool for guiding personalized treatment in endometrial cancer (EC) and atypical endometrial hyperplasia (AEH). This retrospective study aimed to assess the impact of molecular classification on fertility-sparing treatment outcomes in patients diagnosed with EC and AEH who underwent fertility preservation therapy between 2006 and 2021. Patients were categorized into four molecular subtypes using immunohistochemistry (IHC) and Sanger sequencing, based on the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE): POLE-ultramutated, mismatch repair (MMR) deficient (MMRd), p53 abnormal (p53abn), and p53 wild-type (p53wt).

View Article and Find Full Text PDF

Deficiency in genes leads to impediment in DNA repair and is associated with an increased lifetime risk of breast, ovarian, prostate, and pancreatic cancer and melanoma. Lynch syndrome is caused by inherited mutations in genes responsible for DNA mismatch repair, with resultant increase in lifetime risk of colorectal, endometrial, ovarian, stomach, urinary, pancreatic, and CNS malignancies. Here, we present a patient with a rare coexistence of both and mutation in the setting of metastatic pancreatic and prostate cancer.

View Article and Find Full Text PDF

Objective: To identify molecular subgroups in endometrioid endometrial cancer (EEC), evaluate their association with clinicohistopathological characteristics, and define low-intermediate risk groups by integrating these parameters.

Methods: This retrospective-cohort study included 1,040 patients who underwent surgery between January 2000 and June 2022. Among 900 EEC cases, 72 recurred.

View Article and Find Full Text PDF